Free Trial
→ Here’s How to Claim Your Stake in Elon’s Private Company, xAI (From Brownstone Research) (Ad) Buy BLTE Stock  Free BLTE Stock Alerts

Belite Bio (BLTE) Financials

Belite Bio logo
$59.60 +0.99 (+1.69%)
As of 01:47 PM Eastern
Compare
Annual Income Statements for Belite Bio

Annual Income Statements for Belite Bio

This table shows Belite Bio's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders		 -5.75 -9.67 -13 -32 -36
Consolidated Net Income / (Loss)		 -5.75 -9.67 -13 -32 -36
Net Income / (Loss) Continuing Operations		 -5.75 -9.67 -13 -32 -36
Total Pre-Tax Income 		-5.75 -9.67 -13 -32 -36
Total Operating Income		 -5.74 -9.80 -13 -32 -40
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 5.74 9.80 13 32 40
Selling, General & Admin Expense		 2.06 2.38 3.95 6.82 10
Research & Development Expense		 3.69 7.42 8.87 25 30
Total Other Income / (Expense), net		 -0.01 0.13 0.17 0.05 3.86
Interest Expense		 0.02 0.00 0.02 0.03 0.02
Interest & Investment Income		 0.01 0.01 0.02 0.07 3.74
Other Income / (Expense), net		 0.00 0.13 0.17 -0.00 0.14
Income Tax Expense		 0.00 0.00 0.00 0.01 0.01
Basic Earnings per Share		 ($0.65) ($1.01) ($0.63) ($1.19) ($1.18)
Weighted Average Basic Shares Outstanding		 8.79M 9.57M 19.98M 26.59M 30.54M
Diluted Earnings per Share		 ($0.65) ($1.01) ($0.63) ($1.19) ($1.18)
Weighted Average Diluted Shares Outstanding		 8.79M 9.57M 19.98M 26.59M 30.54M
Weighted Average Basic & Diluted Shares Outstanding		 - - 24.90M 29.15M 31.83M

Quarterly Income Statements for Belite Bio

No quarterly income statements for Belite Bio are available.

Annual Cash Flow Statements for Belite Bio

This table details how cash moves in and out of Belite Bio's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024
Net Change in Cash & Equivalents		 24 -8.27 25 46 -56
Net Cash From Operating Activities		 -4.44 -7.47 -11 -30 -29
Net Cash From Continuing Operating Activities		 -4.44 -7.47 -11 -30 -29
Net Income / (Loss) Continuing Operations		 -5.75 -9.67 -13 -32 -36
Consolidated Net Income / (Loss)		 -5.75 -9.67 -13 -32 -36
Depreciation Expense		 0.02 0.03 0.06 0.14 0.16
Amortization Expense		 0.00 0.00 0.13 0.26 0.29
Non-Cash Adjustments To Reconcile Net Income		 1.35 1.57 1.48 3.82 5.04
Changes in Operating Assets and Liabilities, net		 -0.05 0.60 -0.42 -2.18 1.43
Net Cash From Investing Activities		 -0.02 -0.06 -0.39 -0.06 -111
Net Cash From Continuing Investing Activities		 -0.02 -0.06 -0.39 -0.06 -111
Purchase of Property, Plant & Equipment		 0.00 -0.07 -0.39 -0.06 -0.12
Acquisitions		 - - 0.00 0.00 -0.04
Purchase of Investments		 - - 0.00 0.00 -188
Sale and/or Maturity of Investments		 - - 0.00 0.00 78
Net Cash From Financing Activities		 28 -0.58 37 76 84
Net Cash From Continuing Financing Activities		 28 -0.58 37 76 84
Repurchase of Common Equity		 0.00 -0.82 -1.03 -1.23 -0.37
Issuance of Common Equity		 0.50 0.00 38 55 41
Other Financing Activities, net		 0.09 0.23 0.00 22 42
Cash Interest Paid		 0.02 0.00 0.02 0.00 0.00
Cash Income Taxes Paid		 - 0.00 0.00 0.01 0.01

Quarterly Cash Flow Statements for Belite Bio

No quarterly cash flow statements for Belite Bio are available.

Annual Balance Sheets for Belite Bio

This table presents Belite Bio's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2021 2022 2023 2024
Total Assets		 18 44 95 152
Total Current Assets		 17 43 90 147
Cash & Equivalents		 17 42 88 32
Short-Term Investments		 - - 0.00 113
Accounts Receivable		 0.00 0.00 0.84 0.58
Prepaid Expenses		 0.09 0.72 0.95 1.35
Plant, Property, & Equipment, net		 0.09 0.54 0.49 0.44
Total Noncurrent Assets		 0.82 0.93 4.21 4.62
Intangible Assets		 - - 0.00 0.03
Other Noncurrent Operating Assets		 0.01 0.93 4.21 4.58
Total Liabilities & Shareholders' Equity		 18 44 95 152
Total Liabilities		 1.64 2.77 4.21 6.31
Total Current Liabilities		 1.64 2.10 3.63 6.05
Accrued Expenses		 1.56 1.91 3.33 5.76
Other Current Liabilities		 0.00 0.20 0.31 0.29
Total Noncurrent Liabilities		 0.00 0.67 0.58 0.26
Other Noncurrent Operating Liabilities		 0.00 0.67 0.58 0.26
Total Equity & Noncontrolling Interests		 -15 42 90 146
Total Preferred & Common Equity		 -15 42 90 146
Total Common Equity		 -15 42 90 146
Common Stock		 12 82 162 254
Retained Earnings		 -27 -40 -72 -108
Accumulated Other Comprehensive Income / (Loss)		 -0.20 -0.39 -0.37 -0.66

Quarterly Balance Sheets for Belite Bio

No quarterly balance sheets for Belite Bio are available.

Annual Metrics and Ratios for Belite Bio

This table displays calculated financial ratios and metrics derived from Belite Bio's official financial filings.

Metric 2020 2021 2022 2023 2024
Growth Metrics		 - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -68.37% -29.21% -151.05% -26.01%
EBIT Growth		 0.00% -68.40% -30.86% -150.27% -25.84%
NOPAT Growth		 0.00% -70.59% -30.87% -147.00% -26.30%
Net Income Growth		 0.00% -68.02% -30.85% -150.09% -14.26%
EPS Growth		 0.00% -55.38% 37.62% -88.89% 0.84%
Operating Cash Flow Growth		 0.00% -68.26% -53.30% -160.40% 2.02%
Free Cash Flow Firm Growth		 0.00% 0.00% -81.69% -154.55% -5.46%
Invested Capital Growth		 0.00% 0.00% 59.34% 486.73% -70.45%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00%
Profitability Metrics		 - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.02% 100.00% 100.00% 100.03% 100.02%
Interest Burden Percent		 100.16% 99.95% 99.94% 99.85% 90.67%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% -57.84% -43.45% -47.95% -30.60%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% -1,100.69% -1,791.93%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 0.00% 52.23% -19.71% -47.95% -30.60%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 64.04% -30.48% -34.98% -24.79%
Net Operating Profit after Tax (NOPAT)		 -4.02 -6.86 -8.97 -22 -28
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 0.00% -30.93% -12.19% -14.53% -6.98%
Return On Investment Capital (ROIC_SIMPLE)		 - - -21.63% -24.51% -19.20%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -5.74 -9.67 -13 -32 -40
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -5.73 -9.64 -12 -31 -39
Valuation Ratios		 - - - - -
Price to Book Value (P/BV)		 0.00 0.00 4.36 12.60 12.61
Price to Tangible Book Value (P/TBV)		 0.00 0.00 4.36 12.60 12.62
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 462.17 2,521.10
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.00 -1.09 -1.03 -0.99 -0.99
Leverage Ratio		 0.00 1.10 1.08 1.05 1.04
Compound Leverage Factor		 0.00 1.10 1.08 1.05 0.95
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 190.31% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% -90.31% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 10.43 38.05 161.24 174.13
Noncontrolling Interest Sharing Ratio		 0.00% 190.31% 54.64% 0.00% 0.00%
Liquidity Ratios		 - - - - -
Current Ratio		 0.00 10.66 20.35 24.76 24.31
Quick Ratio		 0.00 10.61 20.01 24.50 24.09
Cash Flow Metrics		 - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -5.41 -9.83 -25 -26
Operating Cash Flow to CapEx		 0.00% -13,346.43% -2,908.12% -47,360.32% -25,201.72%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 -614.54 -1,001.18 -1,319.76
Operating Cash Flow to Interest Expense		 -211.52 0.00 -716.13 -1,193.48 -1,461.70
Operating Cash Flow Less CapEx to Interest Expense		 -211.52 0.00 -740.75 -1,196.00 -1,467.50
Efficiency Ratios		 - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - -
Invested Capital		 0.00 -1.45 -0.59 2.27 0.67
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 -1.45 0.86 2.86 -1.60
Enterprise Value (EV)		 0.00 50 139 1,051 1,694
Market Capitalization		 36 36 181 1,139 1,839
Book Value per Share		 $0.00 ($1.58) $2.08 $3.63 $5.00
Tangible Book Value per Share		 $0.00 ($1.58) $2.08 $3.63 $5.00
Total Capital		 0.00 17 42 90 146
Total Debt		 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.00 -17 -42 -88 -145
Capital Expenditures (CapEx)		 0.00 0.06 0.39 0.06 0.12
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -1.55 -1.39 -1.85 -4.13
Debt-free Net Working Capital (DFNWC)		 0.00 16 41 86 141
Net Working Capital (NWC)		 0.00 16 41 86 141
Net Nonoperating Expense (NNE)		 1.73 2.81 3.67 9.46 8.15
Net Nonoperating Obligations (NNO)		 0.00 -18 -42 -88 -145
Total Depreciation and Amortization (D&A)		 0.02 0.03 0.20 0.40 0.45
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 ($0.63) ($1.19) ($1.18)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 19.98M 26.59M 30.54M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($0.63) ($1.19) ($1.18)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 19.98M 26.59M 30.54M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 24.90M 29.15M 31.83M
Normalized Net Operating Profit after Tax (NOPAT)		 -4.02 -6.86 -8.97 -22 -28
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - -
EBIT to Interest Expense		 -273.48 0.00 -790.94 -1,266.88 -1,992.75
NOPAT to Interest Expense		 -191.43 0.00 -560.92 -886.70 -1,399.86
EBIT Less CapEx to Interest Expense		 -273.48 0.00 -815.56 -1,269.40 -1,998.55
NOPAT Less CapEx to Interest Expense		 -191.43 0.00 -585.54 -889.22 -1,405.66
Payout Ratios		 - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -8.43% -8.14% -3.89% -1.02%

Quarterly Metrics and Ratios for Belite Bio

No quarterly metrics and ratios for Belite Bio are available.

Frequently Asked Questions About Belite Bio's Financials

When does Belite Bio's financial year end?

According to the most recent income statement we have on file, Belite Bio's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Belite Bio's net income changed over the last 4 years?

Belite Bio's net income appears to be on an upward trend, with a most recent value of -$36.14 million in 2024, rising from -$5.75 million in 2020. The previous period was -$31.63 million in 2023.

What is Belite Bio's operating income?
Belite Bio's total operating income in 2024 was -$40.00 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $40.00 million
How has Belite Bio revenue changed over the last 4 years?

Over the last 4 years, Belite Bio's total revenue changed from $0.00 in 2020 to $0.00 in 2024, a change of 0.0%.

How much debt does Belite Bio have?

Belite Bio's total liabilities were at $6.31 million at the end of 2024, a 49.9% increase from 2023, and a 286.0% increase since 2021.

How much cash does Belite Bio have?

In the past 3 years, Belite Bio's cash and equivalents has ranged from $17.34 million in 2021 to $88.16 million in 2023, and is currently $31.68 million as of their latest financial filing in 2024.

How has Belite Bio's book value per share changed over the last 4 years?

Over the last 4 years, Belite Bio's book value per share changed from 0.00 in 2020 to 5.00 in 2024, a change of 500.3%.

Remove Ads

Related Companies

This page (NASDAQ:BLTE) was last updated on 4/15/2025 by MarketBeat.com Staff
From Our Partners
Elon Set to Shock the World by May 1st ?
Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...
Brownstone Research | Sponsored
[Action Required] Claim Your FREE IRS Loophole Guide
This shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...
Colonial Metals | Sponsored
Collect $7k per month from Tesla’s SECRET dividend
Tesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...
Investors Alley | Sponsored
Elon’s Silver Play? Trump Clears the Path
Nothing is confirmed—yet. But Musk has disrupted every industry he's touched, and Trump's policies make the ti...
Priority Gold | Sponsored
Get Your Bank Account “Fed Invasion” Ready with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank ac...
Weiss Ratings | Sponsored
Elon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to Mars
Elon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...
InvestorPlace | Sponsored
The Trump Dump is starting; Get out of stocks now?
The first 365 days of the Trump presidency… Will be the best time to get rich in American history.
Paradigm Press | Sponsored
Trump Orders 'National Digital Asset Stockpile'
‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more traction
Crypto 101 Media | Sponsored